Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 14 Results

Title
Intervention Indication Therapeutic Area Year Actions
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Ovarian cancer Female Reproductive Cancer 2021 View  |  Download
Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2017 View  |  Download
Olaparib for BRCA mutated and high risk HER2 negative breast cancer - adjuvant therapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Breast cancer Breast Cancer 2020 View  |  Download
Olaparib for BRCAm or ATM mutated metastatic castration-resistant prostate cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Olaparib for Metastatic Pancreatic Cancer with gBRCA Mutation Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Pancreatic cancer Gastrointestinal Cancer 2018 View  |  Download
Olaparib in addition to abiraterone for metastatic castration-resistant prostate cancer – First line Abiraterone acetate (Zytiga; Yonsa) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Olaparib maintenance therapy for non-gBRCA mutated high-grade serous ovarian cancer after platinum-based chemotherapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Non-gBRCA mutated high-grade serous ovarian cancer Female Reproductive Cancer 2022 View  |  Download
Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications